^
    Back
    Association details:
    Biomarker:BRCA1 R1443*
    Cancer:Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    fadraciclib (CYC065) (CDK9 inhibitor, CDK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    NPJ Breast Cancer
    Title:

    Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

    Published date:
    08/31/2021
    Excerpt:
    We tested in vivo efficacy of the combination therapy in two PDXs of BLBC origin with pathogenic BRCA1 alterations: BRCA1 R1443* mutation and truncating BRCA1 2080delA mutation...each model was treated with daily gavage of 50 mg/kg olaparib (a PARP inhibitor) and 25 mg/kg fadraciclib...The combination of CDK2 inhibition with PARP inhibition leads to tumor regression and improved survival in BRCA1 mutant PDX models.
    DOI:
    https://doi.org/10.1038/s41523-021-00312-x